SML2873

EIDD-2801

≥98% (HPLC), ribonucleoside analog, powder

• Synonym(e): ((2R,3S,4R,5R)-3,4-Dihydroxy-5-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate, (oh)4Cyd lester, 4-N-HO-Cyd ester, BHC ester, EIDD 1931 5′-isopropylester, EIDD 1931 prodrug, EIDD 2801, EIDD-1931 5′-isopropylester, EIDD-1931 prodrug, EIDD1931 5′-isopropylester, EIDD1931 prodrug, EIDD2801, N4-Hydroxycytidine 5′-isopropylester, N4-OHcyd ester, N4OHcyd ester, NHC ester, beta-D-N4-Hydroxycytidine 5′-isopropylester
• Empirische Formel (Hill-System): C₁₃H₁₉N₃O₇
• CAS-Nummer: 2349386-89-4
• Molekulargewicht: 329.31
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Produktname: EIDD-2801, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C

Beschreibung

Biochem/physiol Actions

Broad antiviral N4-hydroxycytidine (EIDD-1931) prodrug with in vivo efficacy and enhanced oral bioavailability.

EIDD-2801 is an orally active, 5′-isopropylester prodrug form of the antiviral ribonucleoside analog N4-hydroxycytidine (NHC, EIDD-1931) with known anti-viral activity against SARS-CoV, SARS-CoV-2, RSV, influenza A & B (IAV & IBV), HCV, pestivirus, bovine viral diarrhoea virus (BVDV), Ebola (EBOV), Chikungunya (CHIKV), venezuelan equine encephalitis (VEEV). EIDD-2801 is efficiently hydrolyzed to NHC in vivo, being more orally bioavailable than NHC in nonhuman primates and ferrets, while maintaining similar oral bioavailability as NHC in mice. EIDD-2801 displays in vivo efficacy against pandemic and seasonal IAV strains in ferrets (lowest ED = 2.3 and 7 mg/kg b.i.d. p.o., respectively).

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• Was ist los?: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable